Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

T
Taal, Walter

Erasmus Medical Center
(P 316) THE ROLE OF RADIOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Walter Taal
Favorite
(P 505) LOCAL RECURRENCE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS: A MULTICENTER COHORT STUDY
Walter Taal
Favorite
Tabarestani, Troy

Duke University School of Medicine
(P 509) GIANT CELL TUMOR OF BONE IN THE PEDIATRIC POPULATION: A RETROSPECTIVE STUDY HIGHLIGHTING CASES OF METAPHYSEAL ONLY LOCATION AND INCREASED LOCAL RECURRENCE RATES IN SKELETALLY IMMATURE PATIENTS
Troy Tabarestani
Favorite
Tabatabai, Ghazaleh

Department of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, Comprehensive Cancer Center, University Hospital Tübingen and the Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Ghazaleh Tabatabai
Favorite
Tahara, Sayumi

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Sayumi Tahara
Favorite
Tai, Sarah Beishan

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Sarah Beishan Tai
Favorite
Takagi, Michiaki

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Michiaki Takagi
Favorite
Takahara, Daiichiro

Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery
(P 241) ASSOCIATION OF ADC VALUES WITH DESMOID TUMOR SHRINKAGE DURING ACTIVE OBSERVATION
Daiichiro Takahara
Favorite
Takahashi, Masanobu

Tohoku University Hospital
(P 10) ATEZOLIZUMAB IN JAPANESE PATIENTS WITH ADVANCED ALVEOLAR SOFT PART SARCOMA: A MULTI-CENTER, SINGLE-ARM, INVESTIGATOR-INITIATED PHASE 2 TRIAL (NCCH1907)
Masanobu Takahashi
Favorite
Takahashi, Renata

AC Camargo Cancer Center
(P 192) ROLE OF MAGNETIC RESONANCE IMAGING IN THE PREDICTION OF HISTOLOGICAL GRADE IN SOFT TISSUE SARCOMAS.
Renata Takahashi
Favorite
Takasawa, Akira

Sapporo Medical University School of Medicine
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Akira Takasawa
Favorite
Takasawa, Kumi

Sapporo Medical University School of Medicine
(P 391) THE EXPRESSION OF PVR AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN MPNST.
Kumi Takasawa
Favorite
Takashima, Atsuo

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
(P 35) GENOMIC ALTERATIONS IN ADVANCED GASTROINTESTINAL STROMAL TUMORS AS REVEALED BY COMPREHENSIVE GENOMIC PROFILING TESTS
Atsuo Takashima
Favorite
Takashima, Hiroyuki

Hokkaido University
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hiroyuki Takashima
Favorite
Takenaka, Satoshi

Osaka International Cancer Institute
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Satoshi Takenaka
Favorite
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Satoshi Takenaka
Favorite
Talavera, Pablo

Hospital Clinico san Carlos
(P 149) PSYCOLOGICAL SNAPSHOT OF SARCOMA PATIENTS FROM AN ACADEMIC, UNIVERSITY CENTER, HOSPITAL CLÍNICO SAN CARLOS (HCSC), MADRID, A SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN
Pablo Talavera
Favorite
Tammela, Tuomas

MSKCC
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
Tuomas Tammela
Favorite
Tanaka, Yasuhito

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Yasuhito Tanaka
Favorite
Tanas, Munir

University of Iowa
(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Munir Tanas
Favorite
Tan, Chiu Yi

School of Social Policy & Practice, University of Pennsylvania, Philadelphia PA, USA
(P 07) IDENTIFYING CONCERNS OF ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS AND SURVIVORS FOLLOWING FERTIITY PRESERVATION
Chiu Yi Tan
Favorite
Tan, Daniel

Division of Medical Oncology, National Cancer Centre Singapore and Duke-NUS Medical School
(P 353) UPDATED EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Daniel Tan
Favorite
Tang, Alex

Cooperman Barnabas Medical Center/Jersey City Medical Center – RWJBarnabas Health
(P 467) DOES PERIOPERATIVE RADIATION AFFECT IMPLANT SURVIVORSHIP OF PRIMARY TOTAL HIP ARTHROPLASTY IN THE SETTING OF METASTATIC BONE DISEASE: A MULTICENTER STUDY
Alex Tang
Favorite
Tang, Austin

Hospital Authority
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Austin Tang
Favorite
Tang, Chih-Min

Department of Surgery, Division of Surgical Oncology, University of California San Diego
(P 29) COMBINATION TREATMENT WITH TEMOZOLOMIDE AND THE DEATH RECEPTOR-5 AGONIST INBRX-109 EFFECTIVELY TARGETS SUCCINATE DEHYDROGENASE -DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Chih-Min Tang
Favorite
Tang, Whiter

Chris O'Brien Lifehouse
(P 194) REAL WORLD OUTCOMES OF PATIENTS TREATED WITH GEMCITABINE AND DOCETAXEL FOR ADVANCED SOFT TISSUE SARCOMA IN AN AUSTRALIAN SARCOMA CENTRE
Whiter Tang
Favorite
Tang, Xiaodong

Peking University People's Hospital
(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA
Xiaodong Tang
Favorite
(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS
Xiaodong Tang
Favorite
(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING
Xiaodong Tang
Favorite
(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP
Xiaodong Tang
Favorite
(P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL
Xiaodong Tang
Favorite
(P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY
Xiaodong Tang
Favorite
(P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS
Xiaodong Tang
Favorite
(P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES
Xiaodong Tang
Favorite
Tan, Heng

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Heng Tan
Favorite
Tan, Joey

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Joey Tan
Favorite
Tan, Li

The First Affiliated Hospital of Sun Yat-sen University
(P 45) THE LONG-TERM EFFECT OF IMATINIB WITH HEPATIC RESECTION OR OTHER LOCAL TREATMENT FOR GIST LIVER METASTASES
Li Tan
Favorite
Tan, Minjia

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 416) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Minjia Tan
Favorite
Tannenbaum, Allen

Departments of Computer Science and Applied Mathematics and Statistics, Stony Brook University
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Allen Tannenbaum
Favorite
Tan, Qiu Xuan

Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore
(P 336) EVOLUTION AND PURSUIT OF EXCELLENCE IN SARCOMA MANAGEMENT IN AN ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Qiu Xuan Tan
Favorite
Tan, Siwei

Beijing Friendship Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Siwei Tan
Favorite
Tao, Kaixiong

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 38) EFFICACY AND SAFETY OF RIPRETINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER RETROSPECTIVE STUDY
Kaixiong Tao
Favorite
(P 39) MANAGEMENT PRACTICES OF GASTROINTESTINAL STROMAL TUMORS: A QUESTIONNAIRE SURVEY OF GENERAL SURGEONS IN CHINA
Kaixiong Tao
Favorite
Tao, Min

Department of Oncology, The First Affiliated Hospital of Soochow University
(P 44) RIPRETINIB FOR THE TREATMENT OF CHINESE PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBORING KIT SECONDARY MUTATIONS: A MULTICENTER, RETROSPECTIVE STUDY
Min Tao
Favorite
Tao, Ping

Department of Laboratory Medicine, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Ping Tao
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Ping Tao
Favorite
Tap, William

Memorial Sloan Kettering Cancer Center
(P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)
William Tap
Favorite
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
William Tap
Favorite
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
William Tap
Favorite
(P 173) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
William Tap
Favorite
(P 176) SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI–COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 UPDATE
William Tap
Favorite
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
William Tap
Favorite
(P 257) CHARACTERIZING THE EVOLUTION AND THERAPEUTIC RESPONSE OF UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING MOUSE MODELS
William Tap
Favorite
(P 555) A PILOT PHASE II STUDY TO EVALUATE THE SMALL MOLECULE TIGILANOL TIGLATE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: CLINICAL TRIAL IN PROGRESS
William Tap
Favorite
Taritsa, Iulianna

Northwestern Medicine
(P 480) TARGETED MUSCLE REINNERVATION FOR HIP DISARTICULATION - EVALUATION OF EARLY FUNCTIONAL OUTCOMES
Iulianna Taritsa
Favorite
Tasse, Jordan

Rush University Medical Center
(P 377) EFFECTIVENESS OF INTERVENTIONAL RADIOLOGY GUIDED PROCEDURES FOR LOCALLY RECURRENT AND METASTATIC SARCOMA: SINGLE INSTITUTIONAL RESULTS
Jordan Tasse
Favorite
Tat, Candise

Texas Children's Hospital / Baylor College of Medicine Center for Cell and Gene Therapy
(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS
Candise Tat
Favorite
Tawil, Nadim

McGill university
(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA
Nadim Tawil
Favorite
Taylor, Aaron

The Jackson Laboratory for Genomic Medicine
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Aaron Taylor
Favorite
Taylor, Edward

University Health network
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Edward Taylor
Favorite
Taylor, Rachel

University College London Hospitals NHS Trust
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Rachel Taylor
Favorite
Taylor, Stephen

University College London
(P 147) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO DAILY ACTIVITES AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE
Stephen Taylor
Favorite
(P 492) BALANCE AND GAIT OUTCOMES AFTER 1-YEAR POST-OPERATIVE HEMIPELVECTOMY SURGERY
Stephen Taylor
Favorite
(P 493) GAIT KINEMATICS OF SARCOMA PATIENTS AT 1 YEAR POST-OPERATIVE INTERNAL HEMIPELVECTOMY SURGERY: A RETROSPECTIVE STUDY.
Stephen Taylor
Favorite
(P 494) WHAT IS THE EXPERIENCE OF THOSE WITH CANCER-RELATED REDUCED QUALITY OF LIFE AND ASSOCIATED PHYSICAL DISABILITIES AFTER UPPER LIMB SARCOMA TREATMENT IN ENGLAND? A NATIONAL STUDY OF OUTCOMES.
Stephen Taylor
Favorite
(P 495) UNDERSTANDING THE EXPERIENCES OF PATIENTS RETURNING TO ACTIVITIES OF DAILY LIVING AND EXERCISE FOLLOWING LIMB SPARING SURGERY FOR BONE OR SOFT TISSUE SARCOMA AROUND THE KNEE.
Stephen Taylor
Favorite
(P 496) WHAT ARE THE EXPERIENCES OF BALANCE, GAIT AND NEURO-MUSCULAR CONTROL OUTCOMES AFTER PROXIMAL FEMORAL REPLACEMENTS FOR MUSCULOSKELETAL TUMOURS?
Stephen Taylor
Favorite
(P 519) WHAT ARE THE EXPERIENCES OF GAIT, ACTIVITY LEVELS AND PHYSICAL FUNCTIONING IN PROXIMAL FEMORAL REPLACEMENT AFTER MUSCULOSKELETAL TUMORS?
Stephen Taylor
Favorite
(P 560) REAL-WORLD MONITORING OF PHYSICAL ACTIVITY USING AN ACCELEROMETER AFTER LOWER LIMB SURGERY FOR A SARCOMA.
Stephen Taylor
Favorite
(P 561) EXPERIENCE OF PHYSICAL DISABILITIES AND CANCER-RELATED QUALITY OF LIFE AFTER SPINAL TUMORS- STUDY OF A NATIONAL SURVEY IN ENGLAND.
Stephen Taylor
Favorite
(P 563) BALANCE, GAIT AND BIOMECHANICAL COMPENSATIONS DURING DIFFERENT SPEEDS OF WALKING AFTER TREATMENT FOR DISTAL FEMORAL MUSCULOSKELETAL TUMOURS AND ASSOCIATED LIMITATIONS ON RETURN TO NORMAL LIVING
Stephen Taylor
Favorite
Tecson, Kristen

Daiichi Sankyo, Inc.
(P 131) PATIENT-REPORTED CONTINUED BENEFITS IN PATIENTS TREATED WITH PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR BASED ON A REAL-WORLD STUDY IN THE UNITED STATES
Kristen Tecson
Favorite
Tedesco, Giulia

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy
(P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY
Giulia Tedesco
Favorite
Teh, Bin Tean

National Cancer Center Singapore
(P 285) TUMOUR-INFILTRATING MAST CELLS IN ANGIOSARCOMAS CORRELATE WITH CLINCIAL PHENOTYPES AND IMMUNO-ONCOLOGY PATHWAYS
Bin Tean Teh
Favorite
Teicher, Beverly

National Cancer Inst.
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Beverly Teicher
Favorite
Tekkis, Paris

The Royal Marsden Hospital
(P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS
Paris Tekkis
Favorite
Temiz, Nuri

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Nuri Temiz
Favorite
(P 236) APOBEC MUTAGENESIS IN OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND RESPONSE TO THERAPY
Nuri Temiz
Favorite
Teot, Lisa

Boston Children's Hospital and Harvard Medical School
(P 409) IMMUNOHISTOCHEMICAL STAINING FOR MYOGENIN, AP2 BETA AND HMGA2 PREDICT FOXO1 FUSION STATUS IN RHABDOMYOSARCOMA: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Lisa Teot
Favorite
(P 425) CHARACTERIZATION OF RHABDOMYOSARCOMA WITH PAX7::FOXO1 FUSIONS: A REPORT FROM THE SOFT TISSUE COMMITTEE OF THE CHILDREN'S ONCOLOGY GROUP
Lisa Teot
Favorite
(P 438) ALVEOLAR RHABDOMYOSARCOMA WITH "BURKITT-LIKE" MORPHOLOGY IS ASSOCIATED WITH HIGH AMPLIFICATION OF MYCL
Lisa Teot
Favorite
Teres, Raul

Hospital de la Santa Creu i Sant Pau
(P 175) TRABECTEDIN PLUS RADIOTHERAPY ON SYMPHTOMATIC ADVANCED SARCOMA PATIENTS, RESULTS FROM THE SYNERGIAS STUDY: A SPANISH GROUP FOR RESEARCH IN SARCOMA (GEIS) PHASE II STUDY
Raul Teres
Favorite
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Raul Teres
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Raul Teres
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Raul Teres
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Raul Teres
Favorite
Terwisscha van Scheltinga, Cecilia

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Cecilia Terwisscha van Scheltinga
Favorite
Teterycz, Paweł

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 09) A NOMOGRAM MODEL TO PREDICT THE OVERALL SURVIVAL OF ADOLESCENT AND YOUNG ADULT PATIENTS WITH LOCALLY ADVANCED EWING SARCOMA.
Paweł Teterycz
Favorite
Teufel, Michael

Boehringer Ingelheim Pharmaceuticals Inc.
(P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST
Michael Teufel
Favorite
Thavaneswaran, Subotheni

The Kinghorn Cancer Centre, St Vincent's Hospital
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
Subotheni Thavaneswaran
Favorite
Thavarasa, Yanosan

Essen University Hospital
(P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES
Yanosan Thavarasa
Favorite
Thebaud, Estelle

Centre Hospitalier Universitaire
(P 212) REPORT ON THE EWING SARCOMA PATIENTS ENROLLED IN ARM D OF THE ACSE-ESMART TRIAL: PHASE I/II STUDY OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IRINOTECAN IN CHILDREN WITH ADVANCED MALIGNANCIES
Estelle Thebaud
Favorite
Theisen, Emily

Nationwide Childrens Hospital
(P 456) SECLIDEMSTAT TREATMENT BLOCKS THE TRANSCRIPTIONAL FUNCTION OF MULTIPLE FET-FUSION PROTEINS
Emily Theisen
Favorite
Thery, Jean-Christophe

CHU Rouen
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Jean-Christophe Thery
Favorite
Theuer, Charles

TRACON
(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Charles Theuer
Favorite
(P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Charles Theuer
Favorite
Thiele, Andrea

Boehringer Ingelheim Pharma GmbH & Co. KG
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Andrea Thiele
Favorite
Thipphavong, Seng

University Health Network
(P 50) CHARACTERIZATION OF A FAMILIAL GIST KINDRED INTOLERANT TO IMATINIB
Seng Thipphavong
Favorite
Thomas, Barbara

Center for Cancer Research, National Cancer Institute
(P 28) RETROSPECTIVE ANALYSIS OF SUCCINATE DEHYDROGENASE (SDH)-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST) OUTCOMES: AN INTERNATIONAL STUDY OF 256 PATIENTS
Barbara Thomas
Favorite
Thomas, Dafydd

University of Michigan, Department of Pathology
(P 449) CIC-DUX4 sarcomas: A single-center review of clinical features and molecular aberrations identified through DNA sequencing
Dafydd Thomas
Favorite
Thomas, David Morgan

University of New South Wales
(P 386) GENOMIC PROFILING OF GYNAECOLOGICAL SARCOMAS: REPORT FROM THE AUSTRALIA-WIDE PRECISION ONCOLOGY PROGRAM
David Morgan Thomas
Favorite
Thomas, Jacob

University of Southern California, Norris Comprehensive Cancer Center
(P 164) INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
Jacob Thomas
Favorite
Thomas, Paul

St. Jude Children's Research Hospital
(P 528) SAFETY AND TOLERABILITY OF ORAL CYCLOPHOSPHAMIDE AND SORAFENIB WITH INTRAVENOUS BEVACIZUMAB WITH THE ADDITION OF ATEZOLIZUMAB IN PEDIATRIC SOLID TUMOR PATIENTS
Paul Thomas
Favorite
Thomas, Sachdev

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Sachdev Thomas
Favorite
THomas, Stephanie

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Stephanie THomas
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Stephanie THomas
Favorite
Thompson, Matthew

Desert Orthopedics
(P 206) A SINGLE-ARM, PHASE II STUDY OF NEOADJUVANT PEMBROLIZUMAB COMBINED WITH RADIOTHERAPY IN THE PRIMARY TREATMENT OF SOFT TISSUE SARCOMAS.
Matthew Thompson
Favorite
Thompson, Patrick

University of North Carolina Health Care
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Patrick Thompson
Favorite
Thompson, Reid

Oregon Health & Science University
(P 129) LOW RATES OF SERVICE CONNECTIVITY FOR SOFT TISSUE SARCOMA (STS) AMONG ELIGIBLE VIETNAM VETERANS WITH AGENT ORANGE EXPOSURE
Reid Thompson
Favorite
Thompson, Shari

Children's National Hospital
(P 564) A PILOT STUDY OF LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AND MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND FOR TREATMENT OF RELAPSED OR REFRACTORY SOLID TUMORS
Shari Thompson
Favorite
Thornton, Mason

University of Miami Miller School of Medicine
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Mason Thornton
Favorite
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Mason Thornton
Favorite
Thotola, Dinesh

Washington University in St Louis
(P 187) PALLIATIVE LATTICE STEREOTACTIC BODY RADIOTHERAPY FOR PATIENTS WITH SARCOMA
Dinesh Thotola
Favorite
Thway, Khin

The Royal Marsden NHS Foundation Trust
(P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES
Khin Thway
Favorite
(P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL
Khin Thway
Favorite
(P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS
Khin Thway
Favorite
Tian, Hongtao

Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Hongtao Tian
Favorite
Tian, Lantian

The Affiliated Hospital of Qingdao University
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Lantian Tian
Favorite
Tian, Zheng

Department of Orthopaedics, The First Affiliated Hospital of Xinjiang Medical University
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zheng Tian
Favorite
Tibbitts, Justin

University of Minnesota
(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION
Justin Tibbitts
Favorite
Tibbo, Meagan

University of Miami
(P 520) ORTHOPEDIC MANIFESTATIONS OF LYMPHOPROLIFERATIVE NEOPLASMS
Meagan Tibbo
Favorite
Timbergen, Milea J.M.

Erasmus Medical Center
(P 554) FIVE-YEAR OUTCOMES OF A NATIONWIDE PROSPECTIVE CLINICAL TRIAL ON ACTIVE SURVEILLENCE IN PATIENTS WITH NON-INTRAABDOMINAL DESMOID-TYPE FIBROMATOSIS
Milea J.M. Timbergen
Favorite
Timmermann, Beate

University Hospital Essen
(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS
Beate Timmermann
Favorite
(P 451) IMPACT OF TIME TO DIAGNOSIS - A PROSPECTIVE ANALYSIS OF THE EWING 2008 TRIAL
Beate Timmermann
Favorite
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Beate Timmermann
Favorite
Timo, Sara

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Sara Timo
Favorite
Timothy, smile

St. Francis Medial Center
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
smile Timothy
Favorite
Tinoco, Gabriel

Ohio State University
(P 347) INCIDENCE AND TIMING OF RECURRENCE AFTER ADJUVANT PALBOCICLIB IN COMPLETELY RESECTED RETROPERITONEAL LIPOSARCOMA
Gabriel Tinoco
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Gabriel Tinoco
Favorite
Tinteren, Harm

Princess Máxima Center for Pediatric Oncology
(P 558) TRIAL IN PROGRESS: A PHASE 1/2 STUDY OF BRIGATINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA OR INFLAMMATORY MYOFIBROBLASTIC TUMORS (ITCC-098)
Harm Tinteren
Favorite
Tiraboschi, Luca

Humanitas Clinical and Research Hospital
(P 297) UNVEILING THE IMPACT OF INTRATUMORAL MICROBIOTA IN THE TREATMENT EFFICACY OF SOFT TISSUE SARCOMA
Luca Tiraboschi
Favorite
Tirabosco, Roberto

Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK
(P 04) THE CELL ATLAS OF CLEAR CELL SARCOMA
Roberto Tirabosco
Favorite
(P 381) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA
Roberto Tirabosco
Favorite
Tirode, Franck

CENTRE LEON BERARD AND CANCER RESEARCH CENTER OF LYON (INSERM U1052-CNRS5286)
(P 382) NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.
Franck Tirode
Favorite
(P 435) ONCOGENIC FUSION YWHAE::NUTM2 DISRUPT EP300/BCOR INTERACTION
Franck Tirode
Favorite
Titerina, Elizaveta

The Ohio State University Comprehensive Cancer Center
(P 301) REDUCING THE INVASIVE POTENTIAL OF DEDIFFERENTIATED LIPOSARCOMA BY TARGETING ALTERNATIVE RNA SPLICING MACHINERY
Elizaveta Titerina
Favorite
Tlemsani, Camille

APHP
(P 201) PLEOMORPHIC RHABDOMYOSARCOMAS: A NEW ENTITY ASSOCIATED WITH LYNCH SYNDROME? FIRST RESULTS OF SARCLYNCH NATIONAL STUDY
Camille Tlemsani
Favorite
Tokson, Jacqueline Hart

Huntsman Cancer Institute
(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE
Jacqueline Hart Tokson
Favorite
Tolcher, Anthony W.

Clinical Research, NEXT Oncology
(P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES
Anthony W. Tolcher
Favorite
Toledo, Silvia

GRAACC
(P 392) IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF OSTEOSARCOMA
Silvia Toledo
Favorite
Tollit, Anna

Royal National Orthopaedic Hospital NHS
(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)
Anna Tollit
Favorite
Tomazou, Eleni

Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
(P 538) IEUROEWING TRIAL FOR LOCALIZED AND METASTATIC EWING SARCOMA
Eleni Tomazou
Favorite
Tomczak, Katarzyna

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Katarzyna Tomczak
Favorite
Tong, Hanxing

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 339) QUALITY OF SURGERY AND OUTCOME FOR GIANT RETROPERITONEAL LIPOSARCOMA TREATED WITHIN SEMI-ABDOMINAL EN BLOC RESECTION USING VASCULAR PRIORITY CENTRAL APPROACH-A RETROSPECTIVE COHORT
Hanxing Tong
Favorite
(P 398) INTEGRATED MULTI-OMICS APPROACH REVEALED TUMOR-ASSOCIATED TERTIARY LYMPHOID STRUCTURE LANDSCAPE IN RETROPERITONEAL LIPOSARCOMA
Hanxing Tong
Favorite
Tong, Hanxing

Shanghai Zhongshan Hospital
(P 534) NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA
Hanxing Tong
Favorite
Tong, Zhichao

Department of Osteopathic Oncology, Honghui Hospital, Xi'an Jiaotong University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Zhichao Tong
Favorite
(P 543) MANEUVER STUDY: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF PIMICOTINIB (ABSK021) TO ASSESS THE EFFICACY AND SAFETY IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Zhichao Tong
Favorite
Tonini, Giuseppe

Fondazione Policlinico Universitario Campus Bio-Medico
(P 263) HER2 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMAS
Giuseppe Tonini
Favorite
(P 264) CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS AND TRABECTEDIN IN SOFT TISSUE SARCOMA: A NOVEL POTENTIAL SYNERGY?
Giuseppe Tonini
Favorite
Tonon, Laurie

Centre Léon Bérard
(P 104) COMPREHENSIVE IMMUNE PROFILING UNVEILS A SUBSET OF LEIOMYOSARCOMA WITH HOT TUMOR IMMUNE MICROENVIRONMENT
Laurie Tonon
Favorite
Topal, Baki

UZ Leuven
(P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS
Baki Topal
Favorite
Topal, Salih

Foghorn Therapeutics
(P 271) PHARMACODYNAMICS AND MECHANISTIC IMPACTS OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS
Salih Topal
Favorite
Tornero García, José

Universitat Politècnica de Catalunya (UPC), Barcelona, Spain. Cebiotex S.L., Barcelona, Spain
(P 385) FIRST IN HUMAN PHASE I TRIAL OF A NOVEL DRUG DELIVERY IMPLANT MATRIX WITH SN-38 (CEB-01) FOR RETROPERITONEAL SOFT TISSUE SARCOMA
José Tornero García
Favorite
Torre, Maria Luisa

Department of Pharmaceutical Sciences, University of Piemonte Orientale
(P 283) A TRIDIMENSIONAL PRECLINICAL MODEL TO STUDY HUMAN AND CANINE OSTEOSARCOMA DEVELOPMENT AND INTERACTION WITH TUMOR MICROENVIRONMENT
Maria Luisa Torre
Favorite
Torres Sempere, Julio

Hospital Universitary Virgen del Rocio
(P 453) ROLE OF SECOND-LINE TREATMENT IN EWING SARCOMAS WITH POOR PROGNOSIS AT DIAGNOSIS: EXPERIENCE OF A SPANISH REFERENCE CENTER.
Julio Torres Sempere
Favorite
Torres, Keila

The University of Texas MD Anderson Cancer Center
(P 269) PLASMA DNA METHYLATION-BASED BIOMARKERS FOR MPNST DETECTION IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1)
Keila Torres
Favorite
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Keila Torres
Favorite
(P 510) PRIMARY BREAST ANGIOSARCOMA: CLINICAL AND PATHOLOGICAL FEATURES AND IMPACT ON OUTCOMES
Keila Torres
Favorite
Torres, Madeline

University of Texas MD Anderson Cancer Center
(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE
Madeline Torres
Favorite
Torrezan, Giovana

A.C.Camargo Cancer Center
(P 387) CLINICAL CHARACTERIZATION OF PATIENTS WITH LEIOMYOSARCOMA HARBORING THE R337H TP53 GERMINATIVE ALTERATION (LI-FRAUMENI SYNDROME) AND THE PROGNOSTIC IMPLICATION USING A PROPENSITY-SCORE MATCHED COHORT
Giovana Torrezan
Favorite
Tortorelli, Ilaria

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 171) SEX DIFFERENCES IN OUTCOMES AND TOXICITY IN PATIENTS TREATED FOR SARCOMA IN A REFERENCE CENTER
Ilaria Tortorelli
Favorite
(P 216) BRAIN METASTASES IN SARCOMA: A (NOT SO) RARE EVENT. THE EXPERIENCE OF A HIGH VOLUME CENTER
Ilaria Tortorelli
Favorite
Tortoreto, Monica

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)
Monica Tortoreto
Favorite
(P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL
Monica Tortoreto
Favorite
Toulmonde, Maud

Institut Bergonie
(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)
Maud Toulmonde
Favorite
(P 523) IN-BETWEEN SARCOMA: A CATEGORY OF HIGH RISK OF RECURRENCE AND POOR OUTCOME
Maud Toulmonde
Favorite
Town, Ajia

OHSU Knight Cancer Institute
(P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Ajia Town
Favorite
Tran Nguyen, john

Department of Bioengineering, University of Texas at Dallas
(P 261) EFFICACY OF BET INHIBITORS IN SOLITARY FIBROUS TUMOR: AN IN VITRO EVALUATION
john Tran Nguyen
Favorite
Tran, Thuy

UNIVERSITY OF CALIFORNIA IRVINE
(P 324) EVALUATING THE ROLE OF ADJUVANT RADIATION AFTER WIDE LOCAL EXCISION OF PLEOMORPHIC DERMAL SARCOMA
Thuy Tran
Favorite
Traweek, Ray

MD Anderson
(P 394) LEIOMYOSARCOMA INTRATUMORAL MACROPHAGE INFILTRATES ARE ASSOCIATED WITH DISTINCT CLINICAL AND GENOMIC PRESENTATIONS
Ray Traweek
Favorite
Treckmann, Jürgen

University Hospital Essen
(P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS
Jürgen Treckmann
Favorite
Treckmann, Juergen

University Hospital Essen, Sarcoma Centre
(P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)
Juergen Treckmann
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS
Jonathan Trent
Favorite
(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS
Jonathan Trent
Favorite
(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA
Jonathan Trent
Favorite
(P 128) THE IMPACT OF HISPANIC ETHNICITY IN PRESENTATION AND OUTCOMES OF PATIENTS WITH SYNOVIAL SARCOMA
Jonathan Trent
Favorite
Trent, Jonathan

University of Miami
(P 158) SORAFENIB OR ANTHRACYCLINE-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH PROGRESSIVE DESMOID TUMORS
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 189) INTERNATIONAL RETROSPECTIVE STUDY FROM THE ULTRA-RARE SARCOMA WORKING GROUP ON LOW-GRADE FIBROMYXOID SARCOMA AND SCLEROSING EPITHELIOD FIBROSARCOMA: OUTCOME OF ADVANCED DISEASE AND SYSTEMIC THERAPIES
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 208) LOW INCIDENCE OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN ADULT SARCOMA PATIENTS RECEIVING DOXORUBICIN AND UPFRONT DEXRAZOXANE
Jonathan Trent
Favorite
(P 225) PAN-SARCOMA DATABASE (PSDB): A MODEL-VIEW-CONTROLLER FRAMEWORK UTILIZING REDCAP, SHINY, AND R TO CREATE A CONTINUOUS PIPELINE OF SARCOMA DATA
Jonathan Trent
Favorite
(P 226) SIGNATERA TESTING TO IDENTIFY MINIMAL RESIDUAL DISEASE IN HIGH GRADE SARCOMA
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 280) A CELL-BASED COMPOUND SCREENING IDENTIFIES AGENTS THAT SYNERGIZE WITH EVEROLIMUS IN SARCOMA
Jonathan Trent
Favorite
(P 326) MOLECULAR LANDSCAPE OF ENDOMETRIAL STROMAL SARCOMA IN A LARGE REAL-WORLD PATIENT COHORT
Jonathan Trent
Favorite
(P 361) MOLECULAR CHARACTERIZATION OF SOLITARY FIBROUS TUMORS BY ANATOMIC SITE AND NAB2::STAT6 FUSION VARIANT TYPE
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 366) SURVIVAL DISPARITIES IN HISPANIC PATIENTS WITH SARCOMA TESTED WITH NEXT-GENERATION SEQUENCING (NGS)
Jonathan Trent
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami
(P 401) OVEREXPRESSION OF CYCLIN DEPENDENT KINASES AND CYCLINS ACROSS SARCOMAS BEYOND CDK4
Jonathan Trent
Favorite
(P 461) OUTCOMES FOR OLIGOMETASTATIC PULMONARY DISEASE RECURRENCE TREATED WITH SURGERY ALONE FOR PATIENTS WITH SOFT TISSUE SARCOMAS A CASE SERIES
Jonathan Trent
Favorite
(P 550) ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION SOLID TUMORS
Jonathan Trent
Favorite
Trepel, Martin

Department of Hematology and Medical Oncology, University Hospital Augsburg, 86156 Augsburg, Germany
(P 557) UNRAVELING THE ROLE OF LOCAL THERAPY FOR PATIENTS WITH OLIGOMETASTATIC SOFT TISSUE SARCOMA - A RETROSPECTIVE MULTICENTER TRIAL OF BAVARIAN UNIVERSITY HOSPITALS
Martin Trepel
Favorite
Trimm, Conner

University of California San Diego School of Medicine
(P 489) SIMULTANEOUS VERSUS DELAYED FLAP RECONSTRUCTION FOLLOWING SOFT TISSUE SARCOMA RESECTION
Conner Trimm
Favorite
(P 490) TOPICAL ANTIBIOTICS DECREASE INFECTIONS IN EXTREMITY SARCOMA SURGERY
Conner Trimm
Favorite
Trissal, Maria

Dana-Farber Cancer Institute
(P 384) SYSTEMATIC LITERATURE AND CLINICAL TRIAL REVIEW SHOWS TARGETABLE KINASE FUSIONS ARE COMMON IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SOFT TISSUE SARCOMAS BUT CLINICAL TRIAL OPPORTUNITIES REMAIN RARE
Maria Trissal
Favorite
Trovillion, Erin

Atrium Health - Levine Children's Hospital
(P 266) ROMIDEPSIN DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Erin Trovillion
Favorite
Trpkov, Kiril

Alberta Precision Laboratories, Staff Pathologist
(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS
Kiril Trpkov
Favorite
Trucco, Matteo

Cleveland Clinic
(P 308) OPTIMAL BIOLOGIC EFFECTIVE DOSE OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC AND RECURRENT SARCOMA
Matteo Trucco
Favorite
(P 536) PHASE 1 STUDY OF DISULFIRAM WITH COPPER GLUCONATE AND LIPOSOMAL DOXORUBICIN IN PATIENTS WITH TREATMENT REFRACTORY SARCOMAS
Matteo Trucco
Favorite
(P 537) TGFβ IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NATURAL KILLER CELLS WITH CHEMOTHERAPY FOR RELAPSED BONE AND SOFT TISSUE SARCOMA - NCT05634369, REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Matteo Trucco
Favorite
(P 539) SARCOMA STEREOTACTIC BODY RADIOTHERAPY AND IMMUNE SYSTEM TRIAL
Matteo Trucco
Favorite
(P 551) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT RHABDOMYOSARCOMA: A CLINICAL TRIAL IN PROGRESS FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Matteo Trucco
Favorite
Trujillo-Reyes, Juan Carlos

Hospital de la Santa Creu i Sant Pau
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Juan Carlos Trujillo-Reyes
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Juan Carlos Trujillo-Reyes
Favorite
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Juan Carlos Trujillo-Reyes
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Juan Carlos Trujillo-Reyes
Favorite
Trullols Tarrago, Laura

Hospital de la Santa Creu i Sant Pau, Barcelona
(P 503) SCAPULAR PROSTHESIS RECONSTRUCTION, EXPERIENCE IN OUR INSTITUTION
Laura Trullols Tarrago
Favorite
(P 504) WHY DO SOME PATIENTS WITH SYNOVIAL SARCOMA HAVE BETTER FUNCTIONAL OUTCOMES AFTER RESECTION SURGERY? ANALYSIS OF 102 CASES
Laura Trullols Tarrago
Favorite
(P 508) DREAM, UTOPIA OR REALISM? PROGNOSTIC FACTORS IN LUNG METASTASECTOMY OF DISSEMINATED SARCOMA DISEASE
Laura Trullols Tarrago
Favorite
Trullols, Laura

Hospital de la Santa Creu i Sant Pau
(P 507) PRIMARY CHEST WALL TUMORS OF MESENCHYMAL ORIGIN. EXPERIENCE OF A REFERENCE UNIT
Laura Trullols
Favorite
Truong, Danh

The University of Texas MD Anderson Cancer Center
(P 397) A MESENCHYMAL TISSUE LANDSCAPE TO STUDY OSTEOSARCOMA TUMOR HETEROGENEITY
Danh Truong
Favorite
(P 426) MULTI-OMIC ANALYSIS OF DESMOPLASTIC SMALL ROUND CELL TUMORS REVEAL DISTINCT LINEAGES
Danh Truong
Favorite
(P 427) UNDERSTANDING THE MOLECULAR DRIVERS THAT REGULATE EWING SARCOMA CELL FATE
Danh Truong
Favorite
Tsagkozis, Panagiotis

Karolinska Institutet
(P 243) EVALUATION OF THE USE OF WGS IN ROUTINE DIAGNOSTICS FOR BONE AND SOFT TISSUE TUMORS
Panagiotis Tsagkozis
Favorite
Tsagkozis, Panagiotis

Karolinska University Hospital
(P 278) CLINICAL MARKERS PREDICTIVE OF TRABECTEDIN RESPONSE IN SOFT TISSUE SARCOMA
Panagiotis Tsagkozis
Favorite
(P 372) COPY NUMBER GAIN OF MDM2 IN ROD-SHAPED CHROMOSOMES PROVIDES CLUES TO EARLY STAGES IN CIRCULARIZED GENE AMPLIFICATION IN LIPOSARCOMA
Panagiotis Tsagkozis
Favorite
Tsai, Henry

ProCure New Jersey
(P 320) A PROSPECTIVE MULTICENTER EXPERIENCE OF PROTON THERAPY FOR RHABDOMYOSARCOMA AND EWING SARCOMA: OUTCOMES FROM THE PROTON COLLABORATIVE GROUP REGISTRY
Henry Tsai
Favorite
Tseng, Hsian-Rong

David Geffen School of Medicine, University of California, Los Angeles
(P 19) EXTRACELLULAR VESICLE CLICK MAGBEADS: A MULTIFACETED LIQUID BIOPSY PLATFORM FOR PEDIATRIC SARCOMAS
Hsian-Rong Tseng
Favorite
Tseng, William

City of Hope National Medical Center
(P 329) DISTANT METASTASIS IN RETROPERITONEAL LEIOMYOSARCOMA: TUMOR SIZE, GRADE AND MORE?
William Tseng
Favorite
Tse, Pamela

Kaiser Permanente
(P 224) CO-MUTATION-DEPENDENT PROGNOSIS IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA
Pamela Tse
Favorite
Tse, Teresa

Prince of Wales Hospital, Hong Kong
(P 290) PRE-CLINICAL STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ALONE OR IN CONJUNCTION WITH SYSTEMIC THERAPIES IN SELECTED BONE- AND SOFT-TISSUE SARCOMAS
Teresa Tse
Favorite
Tsoi, Kim

University of Toronto
(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?
Kim Tsoi
Favorite
Tsoi, Kim

Mount Sinai Hospital
(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA
Kim Tsoi
Favorite
Tsoi, Kim

University of Toronto
(P 249) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Kim Tsoi
Favorite
(P 284) VALIDATING A NOVEL MICROFLUIDIC PLATFORM AS AN EX VIVO TUMOUR MODEL FOR SARCOMA DRUG DISCOVERY
Kim Tsoi
Favorite
(P 352) DETERMINING THE CONTRIBUTIONS OF STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Kim Tsoi
Favorite
(P 367) CHARACTERIZING HYPOXIA AND ASSOCIATED MOLECULAR FEATURES IN EXTREMITY SOFT TISSUE SARCOMA
Kim Tsoi
Favorite
(P 443) SURGICAL RESECTION OF EXTREMITY EWING'S SARCOMA BASED ON POST-CHEMOTHERAPY TUMOUR VOLUME RESULTS IN SAFE MARGINS
Kim Tsoi
Favorite
(P 483) DID THE COVID-19 PANDEMIC NEGATIVELY AFFECT OUTCOMES FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMAS?
Kim Tsoi
Favorite
(P 484) OBESITY INCREASES THE RISK OF MAJOR WOUND COMPLICATIONS FOLLOWING PELVIC RESECTION FOR BONE SARCOMA
Kim Tsoi
Favorite
Tsuchie, Hiroyuki

Akita University Graduate School Of Medicine
(P 05) COEFFICIENT OF VARIATION OF T2-WEIGHTED MRI PREDICTS THE PROGNOSIS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Hiroyuki Tsuchie
Favorite
(P 469) IMPACT OF A SPECIALIZED OUTPATIENT CLINIC ON BONE MRTASTASIS AND ITS BURDEN ON SPINE SURGEONS
Hiroyuki Tsuchie
Favorite
(P 470) PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL SUBTYPE IN SOFT TISSUE SARCOMA WITH DISTANT METASTASIS
Hiroyuki Tsuchie
Favorite
(P 471) IMPACT OF PRIMARY TUMOR RESECTION ON METASTASIS TO THE LUNG IN PATIENTS WITH BONE AND SOFT-TISSUE SARCOMA
Hiroyuki Tsuchie
Favorite
(P 486) PRIMARY HIGH-GRADE SARCOMA OF THE SPINE: EXPERIENCE WITH 11 CASES
Hiroyuki Tsuchie
Favorite
Tsuchihashi, Kenji

Kyushu University Hospital
(P 547) A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC EPITHELIOID SARCOMA (TAZETTA TRIAL)
Kenji Tsuchihashi
Favorite
Tsuchiya, Hiroyuki

Kanazawa University
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Hiroyuki Tsuchiya
Favorite
Tsukamoto, Shinji

Nara Medical University
(P 259) LOVASTATIN INDUCES NOVEL CELL DEATH THROUGH THE IMPAIRED MITOCHONDRIA IRON UTILIZATION IN OSTEOASRCOMA CELLS.
Shinji Tsukamoto
Favorite
Tsukushi, Satoshi

Aichi Cancer Center Hospital
(P 396) COMPREHENSIVE WHOLE-GENOME MOLECULAR PROFILING IN BONE AND SOFT TISSUE SARCOMA: MULTI-OMICS ANALYSIS OF 627 CASES ACROSS HISTOLOGIC SUBTYPES
Satoshi Tsukushi
Favorite
Tu, Chongqi

Department of Orthopedics, West China Hospital, Sichuan University
(P 169) UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B
Chongqi Tu
Favorite
Tufaro, Anthony

Cleveland Clinic
(P 177) ANGIOSARCOMA: AN INCREASING PROBLEM IN THE UNITED STATES
Anthony Tufaro
Favorite
Turaga, Soumya

University of Kansas Medical Centre
(P 446) SYNERGISTIC TARGETING OF KIF11 AND AURKA TO IMPROVE OUTCOMES FOR EWING SARCOMA
Soumya Turaga
Favorite
Turcotte, Robert

Department of Orthopaedic Surgery, McGill University Health Center
(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE
Robert Turcotte
Favorite
Turcotte, Robert

McGill University
(P 379) THE ROLE OF EZHIP IN DRIVING AGGRESSIVE OSTEOSARCOMA
Robert Turcotte
Favorite
Turpin, Brian

Cincinnati Children's Hospital Medical Center
(P 166) SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA
Brian Turpin
Favorite
(P 542) ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
Brian Turpin
Favorite
Turski, Michelle

UCSF
(P 413) LINKING REAL-WORLD CLINICAL AND GENOMIC DATA IN RHABDOMYOSARCOMA: LEVERAGING AACR PROJECT GENIE AS A PATH TOWARD PRECISION ONCOLOGY IN RARE CANCERS
Michelle Turski
Favorite
Tu, Yizheng

UT MD Anderson Cancer Center
(P 203) PRECLINICAL EVALUATION AMG 650, A SMALL MOLECULE INHIBITOR OF KIF18A, IN PEDIATRIC SOLID TUMORS BY THE PEDIATRIC PRECLINICAL IN VIVO TESTING (PIVOT) PROGRAM
Yizheng Tu
Favorite
Tu, Zheng

Cleveland Clinic
(P 429) SARCOMA FUSION GENE ANALYSIS YIELDS PROMISING HLA ANTIGEN FIT IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMOR
Zheng Tu
Favorite
Tydings, Caitlin

Food and Drug Administration
(P 292) APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND THERMAL ABLATION AND BOILING HISTOTRIPSY WITH CHECKPOINT INHIBITORS IN A MURINE MODEL OF OSTEOSARCOMA: AN IN-DEPTH STUDY
Caitlin Tydings
Favorite
Tysarowski, Andrzej

Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 222) EXPLORING THE IMPACT OF NGS ON DIAGNOSTICS AND TREATMENT OF SARCOMA: INSIGHTS FROM REAL-WORLD DATA ACROSS MULTIPLE INSTITUTIONS IN EUROPE
Andrzej Tysarowski
Favorite
Tzanis, Dimitri

Institut Curie
(P 395) TARGETING CD44-MEDIATED IRON ENDOCYTOSIS IN DESMOID FIBROMATOSIS
Dimitri Tzanis
Favorite